Literature DB >> 26857689

Evaluation of topical antifungal products in an in vitro onychomycosis model.

Reindert Sleven1, Ellen Lanckacker1, Peter Delputte1, Louis Maes1, Paul Cos1.   

Abstract

Many topical commercial products are currently available for the treatment of onychomycosis. However, limited data are available concerning their antifungal activity. Using an in vitro onychomycosis model, the daily application of seven nail formulations was compared to the antifungal reference drug amorolfine (Loceryl(®) ) and evaluated for inhibitory activity against Trichophyton mentagrophytes using an agar diffusion test. Of all commercial nail formulations, only Excilor(®) and Nailner(®) demonstrated inhibitory activity, which was much lower compared to the daily application of Loceryl(®) . However, Excilor(®) showed similar efficacy compared to the conventional weekly application of Loceryl(®) . These results suggest a role for organic acids in the antifungal effect of Excilor(®) (acetic acid, ethyl lactate) and Nailner(®) (lactic acid, citric acid, ethyl lactate) as all tested formulations without organic acids were inactive.
© 2016 Blackwell Verlag GmbH.

Entities:  

Keywords:  Trichophyton mentagrophytes; in vitro; onychomycosis; topical antifungals

Mesh:

Substances:

Year:  2016        PMID: 26857689     DOI: 10.1111/myc.12475

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  2 in total

1.  Daily Application of an Aqueous, Acidifying, Peelable Nail Polish versus Weekly Amorolfine for Topical Onychomycosis Treatment: A Prospective, Randomized, Blinded Trial.

Authors:  Frank Eertmans; Nejib Doss; Bart Rossel; Els Adriaens
Journal:  Dermatol Ther (Heidelb)       Date:  2018-07-26

2.  Polishing the Therapy of Onychomycosis Induced by Candida spp.: Amphotericin B-Loaded Nail Lacquer.

Authors:  Aleph M S Souza; Renato C A Ribeiro; Gleyse K L O Pinheiro; Francisco I Pinheiro; Wógenes N Oliveira; Luanda B F C Souza; André L Silva; Lucas Amaral-Machado; Éverton N Alencar; Guilherme M Chaves; Eryvaldo S T Egito
Journal:  Pharmaceutics       Date:  2021-05-24       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.